Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
H
Haegele, Joseph
Wave Life Sciences
(
W1230-02-06
)
Strategies for the Development and Characterization of Sensitive Anti-oligonucleotide Antibodies for Application in Anti-drug Antibody Assays
Joseph Haegele
Favorite
Halpern, Wendy
Genentech, Inc.
(
T1130-02-07
)
Anti-CCR8 Mediated Depletion of Tumor-Infiltrating Regulatory T Cells: Preclinical PK/PD and Translational Strategy in Support of Clinical Development for Solid Tumor Indications
Wendy Halpern
Favorite
Haltaufderhyde, Kirk
EpiVax, Inc.
(
W1230-02-11
)
Comprehensive Assessment of Immunogenicity Risk of Host Cell Proteins in Biologics and Vaccines Using In Silico and In Vitro Methods
Kirk Haltaufderhyde
Favorite
Hamm-Alvarez, Sarah
University of Southern California
(
W1230-01-03
)
Elastin-Like Polypeptide (ELP) Antibody Fusions Targeting IL-6: Pharmacology and Pharmacokinetics
Sarah Hamm-Alvarez
Favorite
Han, Yi-Chun
Cellentia, Inc.
(
W1430-02-08
)
In Vitro Method Using Circulating Tumor Cells-Derived Organoids from Patients with Solid Tumors to Transform Oncology Drug Development
Yi-Chun Han
Favorite
Haridas, V
Indian Institute of Technology
(
W1030-02-07
)
Comparative Analyses of Thermal Stability Amplifying Peptide Dendrons and Polysorbates
V Haridas
Favorite
Hasebe, Takashi
Eisai Co., Ltd.
(
T1330-01-01
)
Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides II Circular Dichroism Spectroscopy and Nuclear Magnetic Resonance Analysis for Determining Higher-Order Structure
Takashi Hasebe
Favorite
Haworth, Ian
University of Southern California
(
W1130-02-08
)
Oral Absorption of Semaglutide: Pharmacokinetic Modeling and Molecular Dynamics Simulations
Ian Haworth
Favorite
Hedström, Kira
Gyros Protein Technologies
(
W1130-02-11
)
Comparison of a Microfluidic Generic Total Antibody (TAb) Assay with Independent Neutralizing Antibody (NAb) and TAb Assays for the Detection of Pre-existing Antibodies against AAV Vectors
Kira Hedström
Favorite
Hendricks, Robert
Genentech, Inc.
(
T1530-02-08
)
Cross Validation of Pharmacokinetic Assays: Experimental and Statistical Design
Robert Hendricks
Favorite
Hernandez-Barry, Hilda
Genentech, Inc.
(
T1030-02-09
)
Evaluating the Effects of Differently Charged Linker-Drugs on Pharmacokinetics and Tissue Distribution of Antibody Drug Conjugates
Hilda Hernandez-Barry
Favorite
Herraez-Baranda, Luis
F. Hoffmann-La Roche Ltd.
(
T1230-02-09
)
Population Pharmacokinetics and Exposure-Efficacy and -Safety Analyses of Atezolizumab for Subcutaneous Injection in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer
Luis Herraez-Baranda
Favorite
Hirokawa, Mai
Mitsubishi Tanabe Pharma Corporation
(
T1030-01-01
)
Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides
Mai Hirokawa
Favorite
(
W1030-01-01
)
Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides III Thermodynamic Analysis on Higher-Order Structure of Oligonucleotides
Mai Hirokawa
Favorite
Ho, Jason
Genentech, Inc.
(
T1030-02-09
)
Evaluating the Effects of Differently Charged Linker-Drugs on Pharmacokinetics and Tissue Distribution of Antibody Drug Conjugates
Jason Ho
Favorite
Homan, Ying
Merck & Co., Inc.
(
W1330-02-11
)
One Drop of Blood, Multiple Sets of Data --- Establishing A Common Protocol for Serotype Specific IGG Concentration Testing Using Mitra® VAMS Dry Blood Samples to Support Vaccine Clinical Studies
Ying Homan
Favorite
Hoover, Clare
AstraZeneca
(
W1230-02-09
)
LC-MS FFPE Tissue Analysis Across Multiple Murine Tissues Supports Mouse Relevance for On-Target/Off-Tumor Toxicity Assessment for Anti-STEAP2 CAR-T Therapeutic Development
Clare Hoover
Favorite
Hoover, Gillian
LabCorp
(
W1230-01-05
)
Development of a Marburg Self-amplifying mRNA-Lipid Nanoparticle Vaccine: Differential Effects When Co-formulated with Toll Receptor Agonists
Gillian Hoover
Favorite
Horst, Sarah
LabCorp
(
W1230-01-05
)
Development of a Marburg Self-amplifying mRNA-Lipid Nanoparticle Vaccine: Differential Effects When Co-formulated with Toll Receptor Agonists
Sarah Horst
Favorite
Hosseini, Iraj
Genentech, Inc.
(
T1130-02-07
)
Anti-CCR8 Mediated Depletion of Tumor-Infiltrating Regulatory T Cells: Preclinical PK/PD and Translational Strategy in Support of Clinical Development for Solid Tumor Indications
Iraj Hosseini
Favorite
Hou, Xiaoqiang
AliveX Biotech
(
T1030-02-06
)
A Mechanistic Model of IgG4-RD Identifies High-Potential Therapy Targets
Xiaoqiang Hou
Favorite
Hsieh, SuChun
Merck & Co., Inc.
(
T1230-02-08
)
Quantitation of Soluble Tumor-Associated Antigens (sTAA) in Tumor Interstitial Fluid (TIF) Isolated from Frozen Solid Tumors
SuChun Hsieh
Favorite
Hsu, Jing-Ya
National Taiwan University
(
W1030-02-10
)
Delivery of Carbonic Anhydrase 9 siRNA by Lipid Nanoparticles
Jing-Ya Hsu
Favorite
Huang, Catherine
Genentech, Inc.
(
T1230-02-10
)
Development of a Highly Sensitive Immunoassay to Measure Circulating Levels of a Nanobody-Based Imaging Agent
Catherine Huang
Favorite
Huang, Lichun
Cellentia, Inc.
(
T1330-02-10
)
Novel Immunoassay Technology: Evaluating the PIXI Platform for Rapid Quantitation with Automation, Wide Dynamic Range, and Small Sample Volume Requirement
Lichun Huang
Favorite
Huang, Weize
Genentech, Inc.
(
T1430-02-09
)
Bridging Bevacizumab PK from Adults to Pediatrics through PBPK Modeling
Weize Huang
Favorite
Huffnagle, Ian
Merck & Co., Inc.
(
T1530-02-09
)
False Positive or Not? – Assessing Potential Interference of Soluble Target to ADA Detection for a Clinical Stage Program
Ian Huffnagle
Favorite
Hughes, Krystal
West Virginia University
(
T1430-01-04
)
Ionizable Lipid Nanoparticles for Dual siRNA/Chemotherapy Delivery for B-cell ALL Treatment
Krystal Hughes
Favorite
Hu, Qiaobin
Croda, Inc.
(
T1330-01-05
)
Optimizing Lipid Nanoparticles (LNPs) Processing for siRNA Delivery by Microfluidics System
Qiaobin Hu
Favorite
Huseni, Mahrukh
Genentech, Inc.
(
T1130-02-07
)
Anti-CCR8 Mediated Depletion of Tumor-Infiltrating Regulatory T Cells: Preclinical PK/PD and Translational Strategy in Support of Clinical Development for Solid Tumor Indications
Mahrukh Huseni
Favorite
